GE HealthCare Results Top Estimates But Firm Cuts Profit Outlook Over Tariffs
GE HealthCare Technologies (GEHC) on Wednesday posted first-quarter results that came in better than analysts had expected, but the former General Electric division lowered its full-year profit outlook because of tariffs.
Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings?
GEHC Q1 results are likely to reflect strong growth in Imaging, Ultrasound, and AI, fueled by robust procedure volumes and global partnerships despite China headwinds.
Stay Ahead of the Game With GE HealthCare (GEHC) Q1 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top -and-bottom-line estimates for GE HealthCare (GEHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
GE HealthCare (GEHC) Surges 10.6%: Is This an Indication of Further Gains?
GE HealthCare (GEHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cincinnati Children's and GE HealthCare build collaborative research program to drive pediatric imaging innovation
CHICAGO--(BUSINESS WIRE)--Cincinnati Children's and GE HealthCare (Nasdaq: GEHC) will form a strategic research program focused on driving clinical and technical research to advance innovation for pediatric care delivery across modalities, including magnetic resonance imaging (MRI), ultrasound, molecular imaging (MI), and computed tomography (CT). The research program will establish the first pediatric Care Innovation Hub nationwide, representing a new model established by GE HealthCare and Cin.
GE HealthCare: Looking Healthier Here
GE HealthCare, spun off from GE in early 2023, has seen its stock trade between $60-$90, now trading at the low end of the range. The company reports nearly $20 billion in sales and is gradually posting higher margins, looking to expand these to the 20% mark. For 2025, GE HealthCare expected 2-3% sales growth and a 40-50 basis point EBIT margin improvement, with free cash flow over $1.75 billion.
GE HealthCare and FPT Expand Strategic Partnership to Drive AI-Powered Healthcare Innovation
HANOI, Vietnam--(BUSINESS WIRE)-- #FPT--Global IT firm FPT and GE HealthCare announced a Strategic Cooperation Agreement, expanding their commercial alliance to advance product strategy and development, and establish an FPT Competency Center in Vietnam. This deepening collaboration reflects a strategic shift from project-based engagement to a long-term alliance aimed at accelerating the adoption of AI-driven solutions, enhancing operational efficiency, and improving patient care. As part of the commer.
GEHC Stock Gains Following Buyout Completion to Boost Its PDx Arm
GE HealthCare aims to expand its existing footprint and offerings in Japan, as well as enhance patient access to next-generation radiopharmaceuticals via its latest acquisition.
GEHC Stock May Rise as Revolution Vibe CT Enhances Imaging Tech
GE HealthCare introduces Revolution Vibe CT, a cutting-edge imaging system designed to enhance diagnostic precision, improve workflow efficiency, and expand accessibility.
GE HealthCare's Latest Product Launch to Boost Cardiology Care
GEHC's latest commercial launch of Flyrcado and the grant of pass-through status by CMS aim to serve a wider patient pool across the United States.
GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan
CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecu.
